Abliva
Abliva AB Interim Report January – June 2023
REG
The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Second quarter summary
Important events second quarter (Apr – Jun 2023)
- The first patient was dosed in Abliva’s global, potentially registrational, clinical Phase 2 study with lead drug candidate KL1333 - the FALCON study.
- Abliva’s drug candidate NV354 was granted Orphan Drug Designation (ODD) in the U.S. for the treatment of mitochondrial disease.
- Abliva’s Annual General Meeting was held on May 5. All proposals were passed by the general meeting. For more information, see Abliva’s website www.abliva.com.
Financial information
April-June 2023*
- Net revenues: SEK 0 (0)
- Other operating income: SEK 2,711,000 (0)
- Loss before tax: SEK 21,226,000 (20,535,000)
- Loss per share before dilution: SEK 0.02 (0.04)
- Diluted loss per share: SEK 0.02 (0.04)
January-June 2023*
- Net revenues: SEK 0 (0)
- Other operating income: SEK 3,766,000 (0)
- Loss before tax: SEK 37,318,000 (42,564,000)
- Loss per share before dilution: SEK 0.04 (0.09)
- Diluted loss per share: SEK 0.04 (0.09)
* APM Alternative performance measures, see definition on page 20.
The complete Interim report is available for download below and through Abliva's website www.abliva.com.
Datum | 2023-08-18, kl 08:30 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)